Back to top
more

Galena Biopharma, Inc. (GALE)

(Real Time Quote from BATS)

$0.26 USD

0.26
NA

-0.01 (-5.11%)

Updated Dec 29, 2017 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Ultragenyx's Hypophosphatemia Drug Succeeds in Phase III

Ultragenyx Pharmaceutical Inc. (RARE) and its Japanese partner Kyowa Hakko Kirin Co., Ltd announced positive data from a phase III study evaluating its pipeline candidate burosumab (KRN23) in adults with X-linked hypophosphatemia (XLH).

    Arena Pharma (ARNA) Down After Underwritten Public Offering

    Arena Pharmaceuticals, Inc.'s (ARNA) shares dropped more than 13% on Apr 18, after the company announced that it will be raising funds through an underwritten public offering.

      Bristol-Myers and Nordic Ink Biomarker Collaboration Deal

      Bristol-Myers Squibb Company (BMY) recently announced that it has inked a collaboration agreement with Nordic Bioscience, a Danish company specializing in biomarker technologies.

        Rigel Pharmaceuticals Files NDA for Thrombocytopenia Drug

        Rigel Pharmaceuticals, Inc. (RIGL) recently announced that it has filed a new drug application (NDA) to the FDA, for its oral spleen tyrosine kinase inhibitor, fostamatinib for the treatment immune thrombocytopenia (ITP).

          Roche's Hemophilia A Drug Positive in Second Phase III Study

          Roche Holding AG's (RHHBY) unit, Genentech, announced positive interim results from the Phase III HAVEN 2 study evaluating its pipeline candidate emicizumab prophylaxis.

            Eli Lilly's Rheumatoid Arthritis Drug Gets CRL in the U.S.

            Eli Lilly and Company (LLY) and its partner Incyte Corporation (INCY) recently announced that they have received a Complete Response Letter (CRL) from the FDA regarding the new drug application (NDA) for baricitinib.

              Biogen to License Alzheimer Candidate from Bristol-Myers

              Biogen Inc. (BIIB) recently announced that it has inked a deal to buy worldwide rights for Bristol-Myers Squibb's (BMY) anti-tau antibody, BMS-986168, for an upfront payment of $300 million.

                Neurocrine's Stock Up, FDA Nod for Tardive Dyskinesia Drug

                Shares of Neurocrine Biosciences, Inc. (NBIX) soared 25% on Tuesday after announcing the FDA approval ofIngrezza (valbenazine) capsules a day before for the treatment of adults with tardive dyskinesia (TD).

                  Roche Launches Antibody Test to Diagnose Prostate Cancer

                  Roche Holding AG (RHHBY) announced that it has launched the anti-p504s (SP116) Rabbit Monoclonal Primary Antibody for prostate cancer diagnosis on a world wise basis.

                    Pacira Focuses on Lead Candidate Exparel's Label Expansion

                    We issued an updated report on Pacira Pharmaceuticals, Inc. (PCRX) on Apr 11.

                      Ohr Pharmaceutical Provides Update on Squalamine Study

                      Ohr Pharmaceutical, Inc. (OHRP), announced it plans to amend the ongoing MAKO Study evaluating Squalamine (also known as OHR-102) in wet form of age-related macular degeneration (wet-AMD).

                        Ultragenyx's (RARE) XLH Drug Positive in Phase II Study

                        Ultragenyx Pharmaceutical Inc. (RARE) and its Japanese partner Kyowa Kirin International plc recently announced positive 64-week data from a pediatric phase II study, evaluating its investigational candidate burosumab (KRN23).

                          Valeant (VRX) Faces Pricing Issues, Generic Threats Loom

                          Shares of Valeant Pharmaceuticals International, Inc. (VRX) hit a 52-week low of $10.08 on Apr 4.

                            Zacks.com featured highlights: EV Energy Partners, OvaScience, Galena Biopharma, Amaya and Cenovus Energy

                            Zacks.com featured highlights: EV Energy Partners, OvaScience, Galena Biopharma, Amaya and Cenovus Energy

                              Jazz Pharma Completes NDA Filing for Leukemia Drug to FDA

                              Jazz Pharmaceuticals plc (JAZZ) recently announced that it has completed the rolling submission of a new drug application (NDA) to the FDA, seeking approval for its leukemia candidate, Vyxeos.

                                What Bargain Hunting? Tap 5 Stocks with Rising P/E Instead

                                These five stocks with rising P/E may cross the barrier of value investing and can offer investors stellar gains.

                                  Bayer Announced Positive Data for Cancer Drug Copanlisib

                                  Bayer Aktiengesellschaft (BAYRY) announced positive data on its experimental candidate copanlisib.

                                    GlaxoSmithKline Initiates Phase III Study with Mepolizumab

                                    GlaxoSmithKline plc (GSK) announced the initiation of a phase III study with Nucala (mepolizumab,) in patients with severe hypereosinophilic syndrome (HES).

                                      Spectrum (SPPI) Initiates Phase II Study for Cancer Candidate

                                      Spectrum Pharmaceuticals (SPPI) recently announced that it has initiated a phase II trial to evaluate its pipeline candidate, poziotinib for the treatment of non-small cell lung cancer patients.

                                        Roche's Rituxan Gets FDA Advisory Committee's Recommendation

                                        Roche Holding AG's (RHHBY) member, Genentech announced that the FDA's Oncologic Drugs Advisory Committee (ODAC) has recommended the approval of subcutaneous Rituxan /hyaluronidase for the treatment of patients with certain blood cancers.

                                          Acorda Presents Data for Parkinson's Candidate CVT-301

                                          Acorda Therapeutics, Inc. (ACOR) announced results from two ongoing, long-term safety studies of CVT-301 in patients suffering with Parkinson's disease.

                                            Amgen's Leukemia Drug Accepted for Priority Review by FDA

                                            Amgen Inc. (AMGN) recently announced that its supplemental biologics license application (sBLA) for its leukemia immunotherapy, Blincyto, has been accepted for priority review by the FDA.

                                              Corcept (CORT) Strives to Commercialize Key Drug Korlym

                                              We issued an updated report on Corcept Therapeutics Incorporated (CORT) on Mar 28.

                                                Vertex Combo Data on Kalydeco+VX-661 Positive in Phase III

                                                Vertex Pharmaceuticals (VRTX) announced positive data from two phase III studies evaluating its lead marketed drug Kalydeco (ivacaftor) in combination with tezacaftor VX-661 (tezacaftor) in patients suffering from cystic fibrosis.

                                                  Tirthankar Chakraborty headshot

                                                  New Strong Buy Stocks for March 20th

                                                  Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Monday